EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

Paulette Magnas iD, Naim Bouazza iD, Frantz Foissac iD, Saïk Urien, Léo Froelicher-Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré und 5 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70620 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Paulette Magnas und 16 weiteren Autor:innen. Beteiligte Einrichtung: U1343, Pharmacologie et Évaluations Thérapeutiques Chez L'enfant et la Femme Enceinte, Inserm, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Chloride Channel Agonists, Cystic Fibrosis, Pregnancy Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Association Vaincre la Mucoviscidose, Filière Maladies Rares MUCO-CFTR, Société Française de la Mucoviscidose.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population. To date, no clinical trials have investigated the effectiveness, safety or PK profiles of ETI during pregnancy. Given the significant physiological changes that occur throughout gestation, which can alter drug PK, characterizing how pregnancy impacts ETI exposure represents a key step towards informing appropriate dosing strategies. Therefore, the aim of this analysis was to assess pregnancy effect on ETI PK.

Method

As part of the French national observational cohort study, therapeutic drug monitoring was performed in 145 wwCF, including 14 pregnant participants. PK profiles for each compound were characterized using the previously published ETI adult population PK model from the same cohort, with model development and evaluation performed using Monolix® software.

Results

A total of 294 plasma samples, including 47 collected from pregnant participants, were drawn during routine clinical care. Pregnancy was found to significantly increase the apparent clearance of tezacaftor (0.97 to 1.44 L/h) and of ivacaftor (9.64 to 11.36 L/h), indicating a decrease in systemic exposure.

Conclusion

These findings raise important questions regarding whether decreased total tezacaftor and ivacaftor exposure may compromise the sustained treatment efficacy. The necessity for dose adjustments during pregnancy remains to be evaluated from a PK (unbound ETI concentrations) and pharmacodynamic (clinical effectiveness) perspective, thus warranting further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chloride Channel AgonistsCystic FibrosisPregnancy ComplicationsAdultFemaleHumansPregnancyYoung AdultAminophenolsBenzodioxolesCohort StudiesDrug CombinationsDrug MonitoringFranceIndolesModels, BiologicalPyrazolesPyrrolidinesQuinolonesQuinuclidinesPyridinesQuinolines

Stichwörter der Autor:innen

cystic fibrosiselexacaftor–tezacaftor–ivacaftorpopulation pharmacokineticspregnancy

Substanzen

AminophenolsBenzodioxolesChloride Channel AgonistsDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazolesPyrrolidinesQuinolones

Autor:innen und Institutionen

  • U1343, Pharmacologie et Évaluations Thérapeutiques Chez L'enfant et la Femme Enceinte, Inserm, Université Paris Cité, Paris, France.
  • Unité de Recherche Clinique, Université Paris Cité Necker/Cochin, Hôpital Tarnier, Paris, France.
  • Service de Pharmacologie Clinique, Hôpital Cochin, AP-HP, Groupe Hospitalier Paris Centre, Paris, France.
  • CIC-1419, Inserm, Hôpitaux Cochin-Necker, Paris, France.
  • Service de Pneumologie, Centre National de Référence de la Mucoviscidose, Hôpital Cochin, AP-HP, Paris, France.
  • Université Paris Cité, Institut Cochin, Inserm U1016, Paris, France.

ORCID-Profile: Paulette Magnas, Naim Bouazza, Frantz Foissac, Jean-Marc Treluyer

Förderung

  • Association Vaincre la Mucoviscidose, Filière Maladies Rares MUCO-CFTR, Société Française de la Mucoviscidose

Zitieren

APA

Magnas, P., Bouazza, N., Foissac, F., Urien, S., Froelicher-Bournaud, L., Lui, G., Guillemart, V., Carlier, N., Da Silva, J., Fesenbeckh, J., Kanaan, R., Honoré, I., Martin, C., Treluyer, J. M., Tsatsaris, V., Burgel, P. R., & Benaboud, S. (2026). Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70620

Vancouver

Magnas P, Bouazza N, Foissac F, Urien S, Froelicher-Bournaud L, Lui G, et al. Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70620

BibTeX
@article{Magnas2026,
  author = {Magnas, Paulette and Bouazza, Naim and Foissac, Frantz and Urien, Saïk and Froelicher-Bournaud, Léo and Lui, Gabrielle and Guillemart, Victoria and Carlier, Nicolas and Da Silva, Jennifer and Fesenbeckh, Johanna and Kanaan, Reem and Honoré, Isabelle and Martin, Clémence and Treluyer, Jean-Marc and Tsatsaris, Vassilis and Burgel, Pierre-Régis and Benaboud, Sihem},
  title = {Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70620}
}
Kostenlos starten →